Short Interest in Century Therapeutics, Inc. (NASDAQ:IPSC) Increases By 14.0%

Century Therapeutics, Inc. (NASDAQ:IPSC - Get Free Report) was the recipient of a large increase in short interest in December. As of December 31st, there was short interest totalling 3,090,000 shares, an increase of 14.0% from the December 15th total of 2,710,000 shares. Based on an average trading volume of 560,600 shares, the short-interest ratio is currently 5.5 days. Currently, 8.9% of the company's shares are sold short.

Institutional Investors Weigh In On Century Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. Geode Capital Management LLC raised its holdings in Century Therapeutics by 3.5% during the 3rd quarter. Geode Capital Management LLC now owns 968,182 shares of the company's stock valued at $1,656,000 after acquiring an additional 32,614 shares during the period. State Street Corp raised its stake in shares of Century Therapeutics by 7.4% during the 3rd quarter. State Street Corp now owns 836,914 shares of the company's stock valued at $1,431,000 after purchasing an additional 57,323 shares during the period. Wellington Management Group LLP purchased a new stake in Century Therapeutics during the 3rd quarter worth about $284,000. Renaissance Technologies LLC lifted its holdings in shares of Century Therapeutics by 6.1% in the second quarter. Renaissance Technologies LLC now owns 165,500 shares of the company's stock worth $422,000 after buying an additional 9,500 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its holdings in Century Therapeutics by 110.1% in the 2nd quarter. Bank of New York Mellon Corp now owns 149,000 shares of the company's stock valued at $380,000 after purchasing an additional 78,088 shares during the period. 50.20% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

IPSC has been the topic of several research analyst reports. HC Wainwright cut their target price on Century Therapeutics from $9.00 to $5.00 and set a "buy" rating on the stock in a research report on Wednesday, November 6th. Chardan Capital cut their price target on Century Therapeutics from $17.00 to $11.00 and set a "buy" rating on the stock in a report on Thursday, November 7th. Finally, Piper Sandler reduced their price objective on shares of Century Therapeutics from $12.00 to $4.00 and set an "overweight" rating for the company in a report on Monday, December 30th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has an average rating of "Buy" and an average target price of $10.00.

Century Therapeutics Trading Up 0.5 %

Shares of IPSC stock traded up $0.00 during trading on Friday, hitting $0.91. The company's stock had a trading volume of 373,338 shares, compared to its average volume of 547,848. The company has a market cap of $77.32 million, a PE ratio of -0.49 and a beta of 1.76. The business has a fifty day moving average of $1.21 and a 200-day moving average of $1.59. Century Therapeutics has a 52 week low of $0.87 and a 52 week high of $5.51.

Century Therapeutics (NASDAQ:IPSC - Get Free Report) last released its earnings results on Tuesday, November 5th. The company reported ($0.37) earnings per share for the quarter, beating analysts' consensus estimates of ($0.45) by $0.08. The firm had revenue of $0.79 million during the quarter, compared to the consensus estimate of $0.47 million. Century Therapeutics had a negative net margin of 4,837.73% and a negative return on equity of 61.66%. During the same period in the prior year, the firm earned ($0.55) EPS. As a group, research analysts predict that Century Therapeutics will post -1.63 EPS for the current year.

About Century Therapeutics

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.